Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Paul G. Richardson, Shaji K. Kumar, Tamás Masszi, Norbert Grzasko, Nizar J. Bahlis, Markus Hansson, Luděk Pour, Irwindeep Sandhu, Peter Ganly, Bartrum W. Baker, Sharon R. Jackson, Anne Marie Stoppa, Peter Gimsing, Laurent Garderet, Cyrille Touzeau, Francis K. Buadi, Jacob P. Laubach, Michele Cavo, Mohamed Darif, Richard LabotkaDeborah Berg, Philippe Moreau

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma'. Together they form a unique fingerprint.

Medicine & Life Sciences